Evolving Treatment Landscape for mHSPC: Latest Clinical Data and Implications for Practice
26/11/2024
0:00
29:13
Did you know androgen deprivation monotherapy is no longer considered standard of care for metastatic hormone-sensitive prostate cancer (mHSPC) by experts?
Credit available for this activity expires: 11/25/25
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001957?ecd=bdc_podcast_libsyn_mscpedu
Mais episódios de "Keeping Current CME"
Não percas um episódio de “Keeping Current CME” e subscrevê-lo na aplicação GetPodcast.